

April 18, 2017

## URGENT FIELD SAFETY NOTICE – FSN 30576

### Access BR Monitor For use with the Access Family of Immunoassay Systems\*

REF	LOT	
387620	All Non-Expired Lots and Future Lots	Multiple

\*The Access Family of Immunoassay Systems includes the Access 2, UniCel DxI 600 and UniCel DxI 800, UniCel Dx C 600i and the UniCel Dx C 660i, UniCel Dx C 680i, UniCel Dx C 860i, and UniCel Dx C 880i systems.

Attention Beckman Coulter Customer,

Beckman Coulter is initiating a field safety corrective action for the product listed above. This letter contains important information that needs your immediate attention.

<b>ISSUE:</b>	Following biases observed in the results of the French National Quality Controls, Beckman Coulter has been informed that a study completed by the French Competent Authority Agence nationale de sécurité du Médicament et des produits de santé (ANSM) showed diagnosed cancer patients in non-remission of their metastatic disease, may have results below the upper reference limit (URL) of 31.3 U/mL as stated in the Access BR Monitor instructions for use (IFU).
<b>IMPACT:</b>	<ul style="list-style-type: none"> <li>The ANSM preliminary study demonstrated that 10 out of 27 patients diagnosed with cancer in non-remission had a result below the Access BR Monitor URL.</li> <li>In this preliminary study, at the cutoff of 31.3 U/mL designated in the Access BR Monitor IFU, the assay achieved a sensitivity of 63% and a specificity of 100% for patients in non-remission.</li> <li>Any changes to the cutoff of the Access BR Monitor assay may impact the sensitivity and specificity of the assay.</li> <li>Reliance on a single numerical result with the Access BR Monitor may inappropriately influence clinical decisions.</li> </ul>



**Move healthcare forward.**

Beckman Coulter Diagnostics Limited  
Lismeehan  
O'Callaghans Mills  
Co. Clare  
Ireland

Telephone +353 65 6831100  
Fax +353 65 6831122  
e-mail [infoie@beckman.com](mailto:infoie@beckman.com)  
Website [www.beckman.com](http://www.beckman.com)

Directors: P Devereux, P Della Puca  
Registered in Ireland no 485929 Registered Office: 70 Sir John Rogerson's Quay, Dublin 2, Ireland

For Beckman Coulter's worldwide office locations and phone numbers, please visit [www.beckmancoulter.com/contact](http://www.beckmancoulter.com/contact)

<b>ACTION:</b>	<p>Ensure your laboratory staff and clinicians are aware of the following limitations of the Access BR Monitor assay found in the IFU:</p> <ul style="list-style-type: none"> <li>• The Access BR Monitor Assay should not be used as a cancer screening tool. A value below the cutoff limit does not indicate the absence of breast cancer.</li> <li>• Serum or plasma CA 15-3 antigen concentrations should not be interpreted as absolute evidence for the presence or absence of cancer.</li> <li>• This device is indicated for use in the measurement of CA 15-3 antigen to aid in the management of breast cancer patients. Serial testing for CA 15-3 antigen concentrations using Access BR Monitor assay should be used in conjunction with other clinical methods for monitoring breast cancer.</li> <li>• The Access BR Monitor results should be interpreted in light of the total clinical presentation of the patient, including: symptoms, clinical history, data from additional tests, and other appropriate information.</li> <li>• Values obtained with different assay methods cannot be used interchangeably. The concentration of CA 15-3 antigen in a given specimen determined with assays from different manufacturers can vary due to differences in assay methods and reagent specificity.</li> <li>• Each laboratory should establish its own reference ranges to assure proper representation of specific populations.</li> </ul>
<b>RESOLUTION:</b>	Beckman Coulter is evaluating the Access BR Monitor cutoff. The conclusions of this evaluation are planned by the third Quarter of 2017.

The national competent authority has been informed of this field safety corrective action.

Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product(s) listed above to another laboratory, please provide them a copy of this letter.

**Please complete and return the enclosed response form within 10 days so that we are assured you have received this important communication.**

If you have any questions regarding this notice, please contact the Customer Support Hotline at 00353 1407 3082 or [techsupportie@beckman.com](mailto:techsupportie@beckman.com).

We apologize for the inconvenience that this caused your laboratory.

Yours sincerely,



Fabien Chirouze  
Quality / Regulatory Affairs Manager - Northern Region Europe  
Tel +44 (0) 1494 429184/+44 (0)1494 429126  
Fax +44 (0) 1494 429182

Enclosed: Vigilance Response Form